Studying Ways to Diagnose Frontotemporal Lobar Degeneration
Observes people with frontotemporal degeneration to improve diagnostic tools for their disorders.
Plain-language title generated from the registry record
Registry title: Diagnosing Frontotemporal Lobar Degeneration
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT02964637, who can take part
Where in Canada
- Toronto Western Hospital, University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT02964637
- Record updated
- 30 March 2025
- Original description
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromesRead full original descriptionShow less
Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
Inclusion: Participant must have a reliable study partner who can provide an independent evaluation of functioning; Able to read, understand and speak English for neuropsychological testing; All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and [18F]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND; Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28.
Exclusion: Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study; History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded; Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body; Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD.